ArticleMedicine2025
Mechanistic insights into Guizhi Fuzi decoction for lumbar disc herniation: Integrating network pharmacology and bioinformatics approach.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The ancient Chinese medical texts have recorded Guizhi Fuzi decoction (GZFZT) as a therapeutic intervention for lumbar disc herniation (LDH), and its clinical efficacy has been validated in medical practice. This research endeavor is specifically designed to delve into and elucidate its precise underlying mechanisms of action, leveraging the sophisticated methodologies of network pharmacology and bioinformatics. In this study, we used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform to extract active compounds and targets from the traditional Chinese medicine GZFZT. Subsequently, we integrated LDH disease target information from DisGeNET, GeneCards, OMIM, and GEO database. By combining this with drug-effective targets, we screened for common targets. Based on these, we conducted protein-protein interaction network analysis and performed gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses on core targets to explore LDH treatment pathways. Finally, we used molecular docking to evaluate potential targets and compounds, identifying the optimal core protein-compound complex. Our study identified 154 active compounds and 230 corresponding targets of GZFZT. Additionally, we collected a total of 1492 LDH disease targets. Topological analysis of the protein-protein interaction network for common drug-disease targets revealed 6 core targets: TNF, STAT3, MAPK1, IL6, MAPK3, and AKT1. Gene ontology enrichment analysis indicated that the mechanism of action of GZFZT is associated with inflammatory responses, apoptotic processes, and oxidative stress states. Kyoto Encyclopedia of Genes and Genomes enrichment analysis suggested that the mechanism of action of GZFZT is closely related to genes involved in the AGE-RAGE and IL-17 signaling pathways. Molecular docking results demonstrated that the selected compounds exhibit strong binding affinity to the targets, indicating their good biological activity. This study unveils novel insights into the active ingredients, targets, and signaling pathways of Guizhi Fuzi decoction in the treatment of lumbar disc herniation. Furthermore, this study suggests that the 3 bioactive components of Guizhi Fuzi decoction (naringenin, β-sitosterol, and stigmasterol) may exert their therapeutic effects on lumbar disc herniation by specifically targeting MAPK3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.